Sign up
Pharma Capital

Q BioMed beefs up its board with half an eye on listing on a national exchange

Dr Panicucci has been providing formulation and development support to Mannin Research on Man01, Q BioMed's glaucoma drug candidate
Board room
Panicucci will be an independent member on the Q board of directors

Q BioMed Inc (OCTMKTS:QBIO) has beefed up its board with the appointment of former Novartis luminary Dr Rick Panicucci as an independent director.

Panicucci is the vice president of pharmaceutical development at STA Pharmaceutical, a WuXi AppTec company.

At WuXi, he is responsible for providing scientific leadership in the areas of developability, formulation development and good manufacturing practice.

Prior to WuXi he held the position of global head of chemical and pharmaceutical profiling at Novartis from 2004 to 2015, where he led the development and implementation of innovative dosage form designs and continuous manufacturing paradigms.

"Rick has played an important role in the early stages of drug discovery and deal making for various companies. We are very pleased to have him join our board and welcome the vast experience and oversight he brings,” said Denis Corin, the chairman and chief executive officer of Q BioMed.

"Having Rick join us as an independent director, is an important corporate governance step as we seek to up-list to a national exchange this year," Corin added.

Why Invest In Q BioMed Inc? Read More Here

Register here to be notified of future QBIO Company articles
View full QBIO profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.